Keep yourself updated with HAEi news and events
HAEi News Archive
KalVista Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
21 March 2024 KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 [...]
Pharvaris announces Phase 3 clinical study design for recently initiated RAPIDe-3 study, and presents QoL improvement and caregiver behavior data
Pharvaris announces Phase 3 clinical study design for recently initiated RAPIDe-3 study, and presents quality-of-life improvement and caregiver behavior [...]
Pharming reports fourth quarter and full year 2023 financial results
Pharming Group reports fourth quarter and full year 2023 financial results Pharming Group presents its preliminary (unaudited) financial report [...]
KalVista awarded UK Promising Innovative Medicine designation for sebetralstat
KalVista Pharmaceuticals awarded UK Promising Innovative Medicine (PIM) designation for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and [...]
KalVista reports third fiscal quarter results and provides operational update
KalVista Pharmaceuticals reports third fiscal quarter results and provides operational update KalVista Pharmaceuticals today provided an operational update and [...]
KalVista to present HAE attack journey data at 2024 HAEi Regional Conference Americas
KalVista Pharmaceuticals to present HAE attack journey data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals today announced the [...]
Astria reports Q4 and full year 2023 financial results and provides a corporate update
Astria Therapeutics reports fourth quarter and full year 2023 financial results and provides a corporate update Astra Therapeutics today [...]
BioCryst reports Q4 and full year 2023 financial results and upcoming key milestones
BioCryst reports fourth quarter and full year 2023 financial results and upcoming key milestones Biocryst Pharmaceuticals Inc today reported [...]
KalVista presents additional phase-3 KONFIDENT data at the 2024 AAAAI Annual Meeting
KalVista Pharmaceuticals presents additional phase-3 KONFIDENT data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting [...]
KalVista presents data on unmet needs in HAE from a Patient Perspective at the 2024 AAAAI Annual Meeting
KalVista Pharmaceuticals presents data on unmet needs in HAE from a Patient Perspective at the 2024 American Academy of [...]
BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment
BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment [...]
Intellia announces Q4 and full-year 2023 financial results and highlights company progress
Intellia Therapeutics announces fourth quarter and full-year 2023 financial results and highlights recent company progress Intellia Therapeutics today reported [...]
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented [...]
Astria to present at upcoming AAAAI Annual Meeting
Astria Therapeutics to present at upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Astra Therapeutics today [...]
BioCryst launches Orladeyo (berotralstat) in Italy
BioCryst launches Orladeyo (berotralstat) in Italy BioCryst Pharmaceuticals Inc today announced that the Italian Medicines Agency, Agenzia Italiana del [...]
KalVista awarded UK innovation passport for sebetralstat
KalVista Pharmaceuticals awarded UK innovation passport for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and Healthcare products Regulatory [...]
KalVista to present phase-3 sebetralstat data at the 2024 AAAAI Annual Meeting
KalVista Pharmaceuticals to present phase-3 sebetralstat data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting [...]
KalVista reports phase-3 KONFIDENT trial meets all endpoints for sebetralstat as first oral on-demand therapy for HAE
KalVista Pharmaceuticals reports phase-3 KONFIDENT trial meets all endpoints for sebetralstat as first oral on-demand therapy for hereditary angioedema [...]
CSL reports net profit after tax for six months ending 31 Dec 2023
CSL reports net profit after tax for six months ending 31 December 2023 CSL Limited announced a reported net [...]
BioCryst to present new Orladeyo (berotralstat) real-world data at 2024 AAAAI annual meeting
BioCryst to present new Orladeyo (berotralstat) real-world data at 2024 American Academy of Allergy, Asthma & Immunology annual meeting [...]
Intellia announces publication of positive interim phase 1 data for NTLA-2002 in HAE patients
Intellia Therapeutics announces publication in the New England Journal of Medicine of positive interim phase 1 data for NTLA-2002 [...]
Successful 2023 HAEi Regional Conference APAC
HAEi’s global advocacy philosophy – think globally, act regionally – was transformed into reality on 17-19 March at the [...]
Successful 2023 HAEi Regional Conference EMEA
Across 1-3 September 2023, the 2023 HAEi Regional Conference EMEA motivated an audience of around 650 HAE patients, caregivers, [...]
Ionis announces positive topline results from study of investigational donidalorsen, and prepares submissions to FDA and EMA
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen, and prepares submissions to US FDA [...]
Pharvaris announces FDA lifting of the clinical hold of deucrictibant for the prophylactic treatment of HAE attacks
Pharvaris announces FDA lifting of the clinical hold of deucrictibant for the prophylactic treatment of HAE attacks Pharvaris today [...]
Countdown to hae day :-) 2024
If it isn’t in your diary already, mark 16 May 2024 for hae day :-) This is our annual [...]
Pharming announces updated 2023 guidance and expects 10% growth in Ruconest revenue
Pharming Group announces updated full year 2023 guidance and expects 10% growth in Ruconest revenue, significantly exceeding prior guidance [...]
HAEi Research in 2023
It has been a research and science-filled year for HAEi. We’ve been active with our research programs, have had [...]
BioCryst announces preliminary 2023 Orladeyo net revenue of $325 million and provides 2024 guidance
BioCryst announces preliminary full year 2023 Orladeyo (berotralstat) net revenue of $325 million, provides 2024 guidance and accelerated path [...]
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
Pharvaris provided business updates and outlined its strategic priorities for 2024. Berndt Modig, Chief Executive Officer of Pharvaris, said: [...]
Intellia highlights its anticipated 2024 key milestones
Intellia Therapeutics highlights its anticipated 2024 key milestones Intellia Therapeutics today announced its strategic priorities through 2026 and key [...]
LEAP Class of 2023: Projects with Member Organizations
Our successful LEAP 2023 Graduates are now well into the project phase of the program. Thanks to their hard [...]
In Their Own Words
As part of the Youngsters' Community Review and Round-up in the December issue of Global Perspectives, two of the [...]
HAEi Youngsters Community Review and Round-Up
Looking Back at 2023 and Forward to 2024 Hello everyone What a year! The Youngsters’ Community goes from strength [...]
All about Women with HAE
In the December 2023 issue of Global Perspectives, we introduced a new, occasional feature called Did You Know? The [...]
Talking to … Quick Fire Questions in HAE
In the December 2023 issue of Global Perspectives, we introduced a new, occasional feature of Global Perspectives, where we [...]
ACARE Answers
We asked ACARE centers from our Asia Pacific, Americas, and EMEA regions to tell us a little about their [...]
All about ACARE
Hello everyone. My name is Rachel. You might’ve met me. I’ve lived with HAE from a very young age, [...]
A New Lease of Life
Across the globe, the HAEi family of Member Organizations (MO) has grown to 99. With such a large number [...]
Advocacy is Proactivity
At the recent 2023 HAEi Regional Conference EMEA, we got to sit down with HAEi Leadership (from left), Henrik [...]
KalVista Announces Publication of First Oral Factor XIIa Data
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology KalVista Pharmaceuticals announced that data [...]
Global Perspectives #3 2023 is ready for you
The last 2023 issue of Global Perspectives magazine is now available for download. Read the latest news and hear from our global [...]
BioCryst announces publication of data from open-label extension of the APEX-2 pivotal trial of Orladeyo (berotralstat)
BioCryst announces publication of data from open-label extension of the APEX-2 pivotal trial of Orladeyo (berotralstat) Biocryst Pharmaceuticals Inc [...]
Ionis announces European licensing agreement with Otsuka for donidalorsen in HAE
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema Ionis Pharmaceuticals Inc today announced that it [...]
CSL’s Garadacimab Receives FDA and EMA Filing Acceptance
CSL's Garadacimab Receives FDA and EMA Filing Acceptance CSL today announced the US Food and Drug Administration (FDA) has [...]
KalVista reports second fiscal quarter results and operational update
KalVista Pharmaceuticals reports second fiscal quarter results and operational update KalVista Pharmaceuticals provided an operational update and released financial [...]
Pharvaris announces positive top-line phase 2 data for prophylactic treatment of HAE attacks
Pharvaris announces positive top-line phase 2 data from the CHAPTER-1 study of deucrictibant for the prophylactic treatment of HAE [...]
BioCryst announces approval of Orladeyo (berotralstat) in Argentina
BioCryst announces approval of Orladeyo (berotralstat) by the National Administration of Drugs, Foods and Medical Devices (ANMAT) in Argentina BioCryst [...]
BioCryst Launches Orladeyo (berotralstat) in Spain
BioCryst Launches Orladeyo (berotralstat) in Spain BioCryst Pharmaceuticals Inc today announced that the Spanish Ministry for Health (Ministerio de Sanidad) [...]
European Commission approves label update for lanadelumab
European Commission approves label update for lanadelumab, for a broader group of pediatric patients with recurrent attacks of hereditary [...]
Intellia receives EU orphan drug designation for NTLA-2002
Intellia Therapeutics receives European Union orphan drug designation for NTLA-2002, an investigational in-vivo CRISPR genome editing treatment for Hereditary [...]
KalVista presents real-world data at the 2023 Annual Scientific Meeting of the ACAAI
KalVista Pharmaceuticals presents real-world data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & [...]
Orchard reports Q3 2023 financial results and highlights recent business accomplishments
Orchard Therapeutics reports third quarter 2023 financial results and highlights recent business accomplishments Orchard Therapeutics announced several business accomplishments [...]
Astria reports Q3 financial results and provides a corporate update
Astria Therapeutics reports third quarter financial results and provides a corporate update Astra Therapeutics reported financial results for the [...]
Kalvista announces Phase-3 KONFIDENT trial milestone
KalVista Pharmaceuticals announces Phase-3 KONFIDENT trial milestone achieved KalVista Pharmaceuticals provided clinical trial and regulatory updates for its lead program [...]
Postcards from Munich and Beyond!
Phew, it has been a whirlwind of activity in the Youngsters’ Community. We’ve just waved goodbye to our friends [...]
2023 US HAEA National Summit – Living Beyond Boundaries
We are all familiar with the enriching conversations, valuable educational content, and unforgettable memories that unfold when a significant [...]
Update from HAEi’s Global Operations
Update from HAEi’s Executive Vice President Global Operations and Chief Compliance Officer, Jørn Schultz-Boysen Great to see so many [...]
Update from HAEi’s Global Advocacy
Update from HAEi’s Executive Vice President Global Advocacy and Chief Diversity Officer, Fiona Wardman Advocacy is an essential tool [...]
Astria presents new Phase 1a data confirming potential for STAR-0125 at the 2023 ACAAI meeting
Astria Therapeutics presents new Phase 1a data confirming potential for STAR-0125 at the 2023 American College Of Allergy, Asthma, [...]
BioCryst presents new real-world data showing reduced attack rates in patients with HAE with normal C1-inhibitor
BioCryst presents new real-world data showing reduced attack rates in patients with HAE with normal C1-inhibitor following long-term treatment [...]
News from Asia Pacific and South Africa
From Regional Patient Advocate Fiona Wardman The countries I look after in the Asia Pacific region have reduced due [...]
News from Eastern Asia
From Regional Patient Advocate Lim Yong Hao I began my official Regional Patient Advocate (RPA) journey in June of [...]
News from South Eastern Europe
From Regional Patient Advocate Natasa Angjeleska This summer was not only for taking time to rest and vacation but [...]
News from Nordics, Germany, Austria, Switzerland, and Israel
From Regional Patient Advocate Jørn Schultz-Boysen Over the past months, the main focus has been the 2023 HAEi Regional [...]
News from Mediterranean, North Africa and British Isles
From Regional Patient Advocate Maria Ferron The main focus during these last 3 months has been the organization of [...]
News from Sub Sahara Africa
From Regional Patient Advocate Patricia Karani The 2023 HAEi Regional Conference EMEA drew the attention of 9 doctors from [...]
News from Central America and Caribbean
From Regional Patient Advocate Javier Santana In Central America and the Caribbean, every day, there are more doctors interested [...]
News from South America and Mexico
From Regional Patient Advocate Fernanda De Oliveira Martins I am working with many countries in my region to support [...]
News from Central Eastern Europe, Benelux and Middle East
From Regional Patient Advocate Michal Rutkowski Hello HAEi Friends! I truly hope you had an enjoyable and relaxing summertime [...]
Ionis presents positive 2-year results from the Phase 2 open label extension study of donidalorsen
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary [...]
Pharming Group announces presentations at ACAAI Annual Scientific Meeting 2023
Pharming Group announces presentations at American College of Allergy, Asthma & Immunology Annual Scientific Meeting in November 2023 Pharming Group [...]
Astria to Present New STAR-0215 Data at the 2023 ACAAI Annual Scientific Meeting
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting [...]
BioCryst announces expected timescales for US filing of Orladeyo for pediatric use
BioCryst announces expected timescales for US filing of Orladeyo for pediatric use during R&D day BioCryst Pharmaceuticals reported that [...]
KalVista to Present Data at the 2023 ACAAI annual scientific meeting
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology [...]
BioCryst reports Q3 2023 financial results with business update
BioCryst reports third quarter 2023 financial results and provides business update BioCryst Pharmaceuticals today reported financial results for the third [...]
Pharvaris to present at the annual scientific meeting of ACAAI 2023
Pharvaris to present at the annual scientific meeting of American College of Allergy, Asthma & Immunology 2023 Pharvaris today announces [...]
Pharming reports Q3 2023 financial results, incl. increased Ruconest revenue
Pharming Group reports third quarter 2023 financial results, including increased Ruconest revenue Pharming Group presents its preliminary, unaudited financial report [...]
BioCryst to present new Orladeyo data at annual scientific meeting of ACAAI
BioCryst to present new Orladeyo (berotralstat) data at annual scientific meeting of American College of Allergy, Asthma & Immunology BioCryst [...]
KalVista Pharmaceuticals Presents Data at the APAAACI 2023 International Conference
KalVista Pharmaceuticals Presents Data at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference KalVista Pharmaceuticals [...]
EMEA – Let’s Take Action
Across 1-3 September, the 2023 HAEi Regional Conference EMEA motivated an audience of around 650 HAE patients, caregivers, [...]
Intellia Receives Priority Medicines (PRIME) Designation From the EMA for NTLA-2002
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002 Intellia Therapeutics, Inc today announced that [...]
Ionis shares significant business and pipeline progress, including on donidalorsen
Ionis shares significant business and pipeline progress at Innovation Day, including on donidalorsen Ionis Pharmaceuticals today held an investor and [...]
Takeda receives CHMP opinion recommending approval of lanadelumab for prevention of HAE attacks in patients aged 2 years and older
Takeda receives CHMP opinion recommending approval of lanadelumab for prevention of HAE attacks in patients aged 2 years and older [...]
ORLADEYO recommended for public reimbursement in Québec, Canada
BioCryst Pharmaceuticals announced that ORLADEYO has been recommended for public reimbursement in Québec, Canada BioCryst Pharmaceuticals today announced that the [...]
KalVista Update on Potential HAE Medicine
KalVista Pharmaceuticals Gives Operational Update on Potential HAE Medicine KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, provided an operational update [...]
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data Astria Therapeutics, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary [...]
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical [...]
Astria Therapeutics to present patient survey data at the 2023 HAEi Regional Conference EMEA
Astria Therapeutics to present patient survey data at the 2023 HAEi Regional Conference EMEA Astria Therapeutics Inc, a biopharmaceutical company [...]
ADARx Pharmaceuticals announces additional funding for clinical trials in HAE and other conditions
ADARx Pharmaceuticals announces additional funding for clinical trials in HAE and other conditions ADARx Pharmaceuticals, a clinical-stage biotechnology company developing [...]
CSL update on HAE clinical development
CSL provided an update on HAE clinical development as part of reporting on annual company results CSL today reported financial [...]
Pharvaris update on clinical development of potential future medicines for HAE
Pharvaris provided an update on the clinical development of potential future medicines for HAE as part of reporting on financial [...]
Ionis provides update on two trials in HAE
Ionis Pharmaceuticals provided an update on two trials in HAE during reporting of financial results for the second quarter of [...]
Astria Therapeutics update on development of STAR-0215 for HAE
Astria Therapeutics provided an update on development of STAR-0215 for HAE as part of reporting on financial results for the [...]
Intellia outlines progress of clinical trials of NTLA-2002
Progress of clinical trials of NTLA-2002 outlined during Intellia Therapeutics' second quarter 2023 financial results presentation Intellia announced that due [...]
Over 70 new US patients enrolled on RUCONEST® in each quarter of 2023
As part of its reporting of the second quarter and the first half of 2023 financial results, Pharming indicated that [...]
BioCryst corporate update
BioCryst Pharmaceuticals provided a corporate update during reporting of financial results for the second quarter ended June 30, 2023 Charlie [...]
Pharvaris presented clinical data at the 2023 U.S. HAEA National Summit
Pharvaris shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416 (deucrictibant immediate-release capsules) for the on-demand treatment of [...]
KalVista Pharmaceuticals New HAE Attack Journey Data at 2023 US HAEA National Summit
KalVista Pharmaceuticals presented data on the hereditary angioedema (HAE) attack journey and a patient preference study at the 2023 US [...]
Be the first to know what’s going on in the world of HAE
[ninja_forms id=3]